Table 1 Baseline cohort characteristics
Variable | Number | Value |
|---|---|---|
Age, median (IQRa), years | 331 | 60 (49.4–68.6) |
Age ≥65 years, n (%) | 331 | 122 (36.9) |
Women, n (%) | 331 | 205 (61.9) |
Current smoker, n (%) | 330 | 69 (20.9) |
Symptom duration, median (IQR), months | 331 | 3.1 (1.7–5.7) |
Body mass index, median (IQR), kg/m2 | 309 | 26.1 (23–29.8) |
25–29.9, n (%) | 104 (33.7) | |
≥30, n (%) | 74 (23.9) | |
Swollen joint count, 28 joints, median (IQR) | 330 | 9 (5–15) |
Tender joint count, 28 joints, median (IQR) | 329 | 9 (4–16) |
Fulfilling 1987 ACR criteria for rheumatoid arthritis, n (%) | 331 | 275 (83.1) |
Fulfilling 2010 EULAR/ACR criteria for rheumatoid arthritis, n (%) | 330 | 281 (85.2) |
Fulfilling 1987 or 2010 sets of criteria for rheumatoid arthritis, n (%) | 330 | 304 (92.1) |
Disease Activity Score, 28 joints-C-reactive protein, median (IQR) | 328 | 5.1 (4.2–6.2) |
Simplified Disease Activity Index, median (IQR) | 328 | 30.1 (19.8–45.2) |
Modified Health Assessment Questionnaire, median (IQR) | 329 | 0.8 (0.4–1.4) |
Total SvH score, median (IQR) | 328 | 2 (0–6) |
SvH erosion score, median (IQR) | 328 | 1 (0–3) |
Erythrocyte sedimentation rate, mm/h, median (IQR) | 331 | 33 (17–46) |
C-reactive protein, mg/L, median (IQR) | 331 | 13.1 (4.5–32.0) |
C-reactive protein >8.0 mg/L | 331 | 207 (62.5) |
Rheumatoid factor-positive, ≥40 IU/ml | 331 | 146 (44.1) |
Anti-CCP2 positive | 331 | 133 (40.2) |
Anti-Sa positive | 331 | 73 (22.1) |
14-3-3η, ng/ml, median (IQR) | 331 | 0.1 (0.0–1.9) |
14-3-3η positive, ≥0.19 ng/ml | 331 | 153 (46.2) |
14-3-3η positive, ≥0.50 ng/ml | 331 | 119 (36.0) |